3rd International HIV/Viral Hepatitis Co-Infection Meeting

HIV / Viral Hepatitis: Improving Diagnosis, Antiviral Therapy and Access
The 3rd International HIV/Viral Hepatitis Co-Infection Meeting, hosted by the International AIDS Society (IAS), takes place just prior to the 21st International AIDS Conference (AIDS 2016) on 17 July, 2016 in Durban, South Africa.

The recent development of highly effective antiviral therapy for HBV and HCV provides the opportunity to counter the rising burden of chronic liver disease among people living with HIV. Global antiretroviral therapy scale-up should limit HBV-related liver disease, through dual antiviral activity. Furthermore, development of antiretroviral therapy delivery infrastructure should enhance implementation of interferon-free DAA regimens for HCV once available. The focus of the meeting is to identify challenges and opportunities for increasing the diagnosis and treatment of viral hepatitis in people living with HIV, particularly in low and middle-income settings.

The 3rd International HIV/Viral Hepatitis Co-Infection Meeting fills a void in the landscape of meetings providing a unique opportunity for industry, academic, community and governmental stakeholders to interact and develop constructive solutions together that can support equitable access to modern therapeutics while maintaining sustainable innovation. The conference provides research-based evidence to demonstrate the value of these curative therapies and engages policy makers towards creating an environment that supports their wider therapeutic access nationally and internationally.

**MEETING OBJECTIVES**

- To review the latest therapeutic developments in viral hepatitis B and C
- To identify challenges and successes in scaling up diagnosis, screening, antiviral treatment and prevention of viral hepatitis in HIV co-infected persons
- To identify how to optimize outcomes and costs to achieve sustainable and equitable access to these therapies globally
- To learn from successful models, such as novel voluntary licensing agreements and map a path toward scaling up of viral hepatitis treatment programmes in low-, middle- and high-income settings
- To advance the agenda for viral hepatitis eradication by assembling key stakeholders for a face-to-face discussion of major barriers and solutions.
<table>
<thead>
<tr>
<th>TIME</th>
<th>SUBJECT</th>
<th>SPEAKER</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:00 – 08:30</td>
<td>Registration</td>
<td></td>
</tr>
<tr>
<td>08:30 – 08:45</td>
<td>Welcome and introduction</td>
<td>Meeting Co-Chair: Wendy Spearman, University of Cape Town</td>
</tr>
<tr>
<td>08:45 – 11:00</td>
<td>Hepatitis B topics</td>
<td>Co-Chairs: Lynne Mofenson, Elizabeth Glaser Pediatric AIDS Foundation, Tongai Maponga, Stellenbosch University</td>
</tr>
<tr>
<td>08:45 – 09:15</td>
<td>HBV-HIV co-infection: Epidemiology, vaccine and treatment coverage</td>
<td>Mark Sonderup, Univeristy of Cape Town</td>
</tr>
<tr>
<td>09:15 – 09:45</td>
<td>PMTCT for HBV</td>
<td>Monique Andersson, Stellenbosch University</td>
</tr>
<tr>
<td>09:45 – 10:15</td>
<td>HBV resistance and escape mutants</td>
<td>Anders Boyd, INSERM</td>
</tr>
<tr>
<td>10:15 – 10:45</td>
<td>Curing HBV: How close are we?</td>
<td>Patrick Kennedy, Barts and The London School of Medicine</td>
</tr>
<tr>
<td>10:45 – 11:00</td>
<td>Panel discussion</td>
<td>Session speakers</td>
</tr>
<tr>
<td>11:00 – 11:30</td>
<td>Break &amp; poster viewing (HBV epidemiology and outcomes)</td>
<td></td>
</tr>
<tr>
<td>11:30 – 12:00</td>
<td>HCC screening and management</td>
<td>Patrick Kennedy, Barts and The London School of Medicine</td>
</tr>
<tr>
<td>12:00 – 12:30</td>
<td>Children and adolescents</td>
<td>Tammy Meyers, Chinese University of Hong Kong; University of the Witwatersrand</td>
</tr>
<tr>
<td>12:30 – 13:30</td>
<td>Lunch &amp; poster viewing</td>
<td>HCV epidemiology and natural history - 12:30 - 13:00</td>
</tr>
<tr>
<td></td>
<td></td>
<td>HCV testing, monitoring and management - 13:00 - 13:30</td>
</tr>
<tr>
<td>13:30 – 15:30</td>
<td>Hepatitis C topics</td>
<td></td>
</tr>
<tr>
<td>13:30 – 14:20</td>
<td>HCV epidemiology: The knowns and the unknowns</td>
<td>Co-Chairs: Julie Bruneau, Université de Montréal, Maria Prins, University of Amsterdam</td>
</tr>
<tr>
<td>TIME</td>
<td>SUBJECT</td>
<td>SPEAKER</td>
</tr>
<tr>
<td>-------------</td>
<td>------------------------------------------------------------------------</td>
<td>------------------------------------------------------------------------</td>
</tr>
<tr>
<td>13:50 – 14:20</td>
<td>Current trends worldwide: Implications for elimination</td>
<td>Margaret Hellard, Burnet Institute</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Margaret Hellard, Burnet Institute</td>
</tr>
<tr>
<td>14:20 – 14:40</td>
<td>Role of resistance and resistance testing for managing HCV</td>
<td>Jürgen Rockstroh, University of Bonn</td>
</tr>
<tr>
<td>14:40 – 15:00</td>
<td>Is a pan-genotypic therapy ready for prime time?</td>
<td>Marina Klein, McGill University; CIHR Canadian HIV Trials Network (CTN)</td>
</tr>
<tr>
<td>15:00 – 15:20</td>
<td>Financing and the scale up of HCV treatments: Entry of generics</td>
<td>Sunil Solomon, Johns Hopkins University School of Medicine</td>
</tr>
<tr>
<td>15:30 – 16:00</td>
<td>Break &amp; poster viewing (HCV treatment access)</td>
<td></td>
</tr>
<tr>
<td>16:00 – 17:15</td>
<td>New tools, new technologies</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Screening for viral hepatitis: Diagnostics (HBV and HCV)</td>
<td>Diana Hardie, University of Cape Town</td>
</tr>
<tr>
<td>16:00 – 16:20</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Screening for viral hepatitis: Liver disease</td>
<td>Wendy Spearman, University of Cape Town</td>
</tr>
<tr>
<td>16:20 – 16:40</td>
<td>WHO Diagnostic Guidelines</td>
<td>Philippa Easterbrook, WHO</td>
</tr>
<tr>
<td>16:40 – 17:00</td>
<td></td>
<td></td>
</tr>
<tr>
<td>17:00 – 17:15</td>
<td>Panel discussion</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Tracy Swan, MSF Access Campaign</td>
</tr>
<tr>
<td>17:15 – 17:25</td>
<td>Opening overview and community perspective</td>
<td></td>
</tr>
<tr>
<td>17:25 – 18:15</td>
<td>Panel discussion</td>
<td></td>
</tr>
<tr>
<td>18:15 – 18:30</td>
<td>Closing remarks</td>
<td></td>
</tr>
</tbody>
</table>

Meeting Co-Chair: Marina Klein, McGill University; CIHR Canadian HIV Trials Network (CTN)
Higher mortality in HIV-HBV co-infected persons with elevated HBV replication in the Temprano Trial

The effect of HIV infection on the age at presentation of HBV-driven hepatocellular carcinoma in South Africa
T. Maponga, H. Vermeulen, B. Robertson, S. Burmeister, W. Preiser, M. Kew, M. Andersson

Impact of antiretroviral therapy on liver stiffness among Zambian adults with HIV-HBV co-infection and HIV mono-infection

Improved liver fibrosis scores in treated HBV/HIV co-infected patients in South Africa despite persistent immune dysregulation
T. Maponga, M. Andersson, J. Taaljaard, C.J. Van Rensburg, W. Preiser, R. Gladshoff

Response to Truvada based cART in HIV/HBV co-infected patients in Botswana

Effect of the timing of hepatitis C virus infection relative to HIV seroconversion on CD4 T cell and HIV RNA evolution among HIV-positive MSM

Hepatitis C prevalence, viral diversity and severity of liver disease in HIV patients in Phnom Penh, Cambodia
A. De Wegheleire, S. An, I. De Baetselier, S. Teav, V. So, S. Thai, S. Francque, L. Lynen

Extremely low hepatitis C antibody prevalence among high-risk, HIV-positive and HIV-negative men who have sex with men and transgender women from community-based organizations in Thailand

Telaprevir containing triple therapy in acute HCV co-infection: the CHAT study

Development and validation of a risk score to assist testing for acute HCV infection in HIV-infected MSM
A.M. Newsum, I.G. Stolte, J.T.M. van der Meer, J. Schinkel, M. van der Valk, J.W. Vanhommerig, A. Buve, M. Danta, A. Hogewoning, M. Prins

Non-invasive serum markers suggest benefit for early ART initiation on liver fibrosis progression within the START study

Ledipasivr/sofosbuvir for 6 weeks in HIV-infected patients with acute HCV infection

SOF/VEL for 12 weeks results in high SVR12 rates in subjects with negative predictors of response to treatment: an integrated analysis of efficacy from the ASTRAL-1, ASTRAL-2, and ASTRAL-3 studies

Retreatment of HCV/HIV co-infected patients who failed 12 weeks of LDV/SOF

Treatment scale-up in Australia to achieve global hepatitis C virus incidence and mortality elimination targets: a cost-effectiveness model
M. Hellard, N. Scott, E. Mcbryde, A. Thompson, J. Doyle

Rapidly falling costs for new hepatitis C direct-acting antivirals (DAAs): potential for universal access
D. Gotham, M. Barber, J. Fortunak, A. Pozniak, A. Hill

Exposure to various combinations of harm reduction strategies in relation to HIV and HCV incidences among PWID in Montreal, Canada
J. Bruneau, D. Jutras-Aswad, G. Zang, É. Roy

Community engagement in universal access to DAA hepatitis C treatment: the Portuguese case
D. Simões, R. Freitas, B. dos Santos, R. Fuertes, L. Mendão

Increasing HCV access through clinical education: medical provider knowledge and practice change intentions
N. Harris, T. Wilder, K. McKinnon, S.H. Kim, A. Urbina
CO-CHAIRS

Marina Klein
McGill University; CIHR Canadian HIV Trials Network (CTN)
Montreal, Canada

Wendy Spearman
Cape Town University
Cape Town, South Africa

OTHER ORGANIZING COMMITTEE MEMBERS

Monique Andersson
Convener of HBV prevention and management theme
Stellenbosch University, Faculty of Health Sciences
Stellenbosch, South Africa

Isabelle Andrieux-Meyer
Co-convener of HCV and HBV access theme
Médecins Sans Frontières (MSF)
Geneva, Switzerland

Anchalee Avihingsanon
Co-convener of Epidemiology and disease burden theme
HIV-NAT
Bangkok, Thailand

Sanjay Bhagani
Co-convener of complex issues in HCV and HBV theme
Royal Free Hospital
London, UK

Christoph Boesecke
EACS Liaison
University of Bonn
Bonn, Germany

Laurent Castera
EASL Liaison
Hôpital Beaujon
Paris, France

Curtis Cooper
Co-convener of HCV therapeutic development theme
The University of Ottawa;
CIHR Canadian HIV Trials Network (CTN)
Ottawa, Canada

Greg Dore
Convener of treatment in special populations theme
Kirby Institute, University of New South Wales
Sydney, Australia

Jordan Feld
Convener of HBV therapeutic development
University of Toronto
Toronto, Canada

Karine Lacombe
Convener of epidemiology and disease burden theme
Hôpital Saint-Antoine
Paris, France

Gail Matthews
Convener of complex issues in HCV and HBV theme
Kirby Institute, University of New South Wales
Sydney, Australia

Sébastien Morin
Point of contact for coordination with the IAS and AIDS2016
International AIDS Society
Geneva, Switzerland

Marion Peters
Co-convener of HBV therapeutic development theme
University of California
San Francisco, USA

Jürgen Rockstroh
Convener of treatment in special populations theme
University of Bonn
Bonn, Germany

Mark Sulkowski
Convener of HCV therapeutic development theme
Viral Hepatitis Center, John Hopkins
Baltimore, USA

Tracy Swan
Convener of HCV and HBV access theme
Médecins Sans Frontières (MSF) Access Campaign
New York, USA